Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system

Cancer Gene Therapy

Volumn 8, Issue 1, 2001, Pages 36-44

  Nagayama, Yuji ^a   Nishihara, Eijun ^a   Namba, Hiroyuki ^a   Yokoi, Haruhiko ^b   Hasegawa, Mamoru ^b   Mizuguchi, Hiroyuki ^c   Hayakawa, Takao ^c   Hamada, Hirofumi ^d   Yamashita, Shunichi ^a   Niwa, Masami ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b DNAVEC Research Inc   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Anaplastic thyroid carcinoma; Competent adenovirus; Cre loxP system; p53 responsive promoter; p53 mutation; Replication

Indexed keywords

CRE RECOMBINASE; GANCICLOVIR; PROTEIN P53;

ADENOVIRUS; ANAPLASTIC CARCINOMA; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; GENE CONTROL; GENE INACTIVATION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; THYROID CARCINOMA; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; CUCUMBER MOSAIC VIRUS;

EID: 20244367717     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700276     Document Type: Article

References (49)

1. Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter
2. Enhanced therapeutic efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system
3. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line
4. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by wild-type tumor suppressor p53 in xenografts of a p53-null thyroid carcinoma cell line
5. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo
6. Replication-selective microbiological agents: Fighting cancer with targeted germ warfare
7. Progress in transcriptionally targeted and regulatable vectors for genetic therapy
8. Database of p53 gene somatic mutations in human tumors and cell lines
9. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas
10. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland
11. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid
12. p53 Tumor suppressor gene therapy for cancer
13. p53-Oriented cancer therapies: Current progress
14. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells
15. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
16. ONYX-015, an E1B gene-attenuated adenovirus, causes tumorspecific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
17. ONYX-015: Clinical data are encouraging
18. The early region lB 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle
19. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
20. Targeting the replication of adenovirus gene therapy vectors to lung cancer cells: The importance of the adenovirus E1b-55kD gene
21. p53-Dependent cell death/apoptosis is required for a productive adenovirus infection
22. p53-Independent and -dependent requirement for E1B-55K in adenovirus type 5 replication
23. The replicative capacities of large E1B-null group A and C adenoviruses are independent of host cell p53 status
24. Infectivity and expression of the early adenovirus proteins are important regulators of wildtype and △E1B adenovirus replication in human cells
25. Development of a novel tumor-specific gene expression system using a p53- responsive promoter
26. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus
27. Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wildtype p53
28. Inhibitory effect of interferon-gamma on the response of human thyrocytes to thyrotropin (TSH) stimulation: Relationship between the response to TSH and the expression of DR antigen
29. Efficient selection for high-expression transfectants with a novel eukaryotic vector
30. Efficient construction of a recombinant adenoviral vector by an improved in vitro ligation method
31. A simple method for constructing El- and E4-deleted recombinant adenoviral vector
32. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase
33. Role of adenovirus E1B proteins in transformation: Altered organization of intermediate filaments in transformed cells that express the 19-kilodalton proteins
34. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome
35. Molecular Cloning: A Laboratory Manual, 2nd ed.
36. Antioncogenic effect of adenovirus E1A in human tumor cells
37. In vivo antitumor effect of retrovirus-mediated gene transfer of the adenovirus E1a gene
38. Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumor immunity
39. Replication-selective adenoviruses as oncolytic agents
40. p53 Selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma
41. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients
42. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
43. Antineoplastic "multimodality adenovirus" containing E1A and a therapeutic transgene
44. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
45. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
46. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
47. A novel tumorspecific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
48. Targeting gene expression to tumor cells with loss of wild-type p53 function